HCR Update from Mark Sanna: The Centers for Medicare & Medicaid Services officially agreed this week to pay for Provenge, an expensive new "vaccine" to treat prostate cancer. CMS announced the final decision to immediately start covering Provenge, which costs $93,000 a patient, and typically gives men suffering from an incurable stage of the disease an extra four months to live.